View All Conferences
NORD Breakthrough Summit 2015
Rare Disease Panel Discussion: Educating Doctors = Earlier Diagnosis
Richard Peters of Genzyme talks about the panel discussion he chaired during the NORD summit about promoting early diagnosis of rare diseases through physician education and awareness.
Advice to New Patient Advocacy Group
Key tip - Join NORD.
Only 4% of Healthcare Business Leaders are Women
We talked with Wendy White, president of the Healthcare Businesswomen's Association about the organization and its goals.
Dohmen's Patient Care Model for Rare Disease
Wendy White, SVP at Dohmen Life Science Services talks about the company's patient care model that is designed to help smaller patient populations such as those found in the rare disease community.
Ocular Melanoma and a Cure in Sight
Zsa Zsa Stallings of Cure in Sight describes her organization and its goals to help patients coping with a diagnosis of ocular melanoma.
The Walking Gallery
At most scientific or medical conferences, you will often see 1 or 2 people wearing a black jacket with a portrait on their back. They are part of the 'Walking Gallery'.
Educating Payors About Rare Diseases
Richard Peters, MD, PhD, head of the global rare disease business unit at Genzyme talks about the importance of educating payors about rare diseases and orphan drugs.
Pfizer's Rare Disease Programs
Bert Bruce at Pfizer talks about some of the programs that his company has in development, including drugs to treat Duchenne muscular dystrophy, sickle cell disease, and hemophilia B.
NORD Summit, Patient Focused Drug Development, and a Gala
At the NORD Rare Diseases and Orphan Products BreakThrough Summit, we talked with Susan Kahn, executive director of the National Tay-Sachs & Allied Diseases Association (NTSAD)
Biomarkers vs Traditional Outcome Measures - What the FDA Thinks
Janet Woodcock, MD, of CDER/FDA talks about the FDA's position on using biomarkers in pivotal clinical trials.
Next Page >>
MOST POPULAR ARTICLES
New Therapies on the Horizon for Huntington's Disease
Developing Personalized CRISPR-Cas9 Genome Editing Therapy for Pompe Disease
Blood Test May Predict Tumor Metastasis in Head and Neck Cancers
Phase 3 Trial Targets Rare Form of Pediatric Epilepsy with No Approved Therapies
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.